Dianthus Therapeutics (NASDAQ:DNTH) Shares Up 5.3% – Still a Buy?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s stock price traded up 5.3% during mid-day trading on Friday . The stock traded as high as $100.55 and last traded at $100.4050. 103,636 shares were traded during trading, a decline of 89% from the average daily volume of 983,946 shares. The stock had previously closed at $95.35.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on DNTH. Raymond James Financial restated a “strong-buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Guggenheim reiterated a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Wall Street Zen raised Dianthus Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Wedbush boosted their price objective on Dianthus Therapeutics from $103.00 to $105.00 and gave the stock an “outperform” rating in a report on Wednesday, May 6th. Finally, Wolfe Research restated an “outperform” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $117.82.

Dianthus Therapeutics Trading Up 10.7%

The business’s fifty day moving average price is $88.97 and its 200-day moving average price is $73.75. The company has a market capitalization of $5.77 billion, a P/E ratio of -25.57 and a beta of 1.20.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Tuesday, May 5th. The company reported ($0.85) EPS for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.22. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%.The business had revenue of $0.46 million for the quarter, compared to analysts’ expectations of $0.40 million. As a group, equities research analysts forecast that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current year.

Insider Transactions at Dianthus Therapeutics

In related news, EVP Ryan Savitz sold 31,249 shares of the firm’s stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $101.03, for a total transaction of $3,157,086.47. Following the transaction, the executive vice president directly owned 31,249 shares of the company’s stock, valued at approximately $3,157,086.47. This trade represents a 50.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Simrat Randhawa sold 26,530 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $90.62, for a total value of $2,404,148.60. Following the completion of the sale, the executive vice president owned 4,000 shares of the company’s stock, valued at $362,480. The trade was a 86.90% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 87,779 shares of company stock worth $7,985,235. 3.02% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Vestal Point Capital LP lifted its holdings in shares of Dianthus Therapeutics by 88.2% in the 2nd quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company’s stock worth $59,616,000 after acquiring an additional 1,499,931 shares during the last quarter. Wellington Management Group LLP grew its holdings in shares of Dianthus Therapeutics by 3,366.9% during the 3rd quarter. Wellington Management Group LLP now owns 2,577,662 shares of the company’s stock valued at $101,431,000 after purchasing an additional 2,503,311 shares during the last quarter. Vanguard Group Inc. raised its position in Dianthus Therapeutics by 24.7% in the 4th quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock worth $84,417,000 after purchasing an additional 406,254 shares during the period. TCG Crossover Management LLC raised its position in Dianthus Therapeutics by 11.7% in the 3rd quarter. TCG Crossover Management LLC now owns 1,676,624 shares of the company’s stock worth $65,975,000 after purchasing an additional 175,000 shares during the period. Finally, State Street Corp lifted its stake in Dianthus Therapeutics by 124.7% in the fourth quarter. State Street Corp now owns 1,507,619 shares of the company’s stock worth $62,129,000 after purchasing an additional 836,571 shares during the last quarter. 47.53% of the stock is currently owned by institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.